SG11202008721SA - Compositions and methods for tcr reprogramming using fusion proteins - Google Patents
Compositions and methods for tcr reprogramming using fusion proteinsInfo
- Publication number
- SG11202008721SA SG11202008721SA SG11202008721SA SG11202008721SA SG11202008721SA SG 11202008721S A SG11202008721S A SG 11202008721SA SG 11202008721S A SG11202008721S A SG 11202008721SA SG 11202008721S A SG11202008721S A SG 11202008721SA SG 11202008721S A SG11202008721S A SG 11202008721SA
- Authority
- SG
- Singapore
- Prior art keywords
- compositions
- methods
- fusion proteins
- reprogramming
- tcr
- Prior art date
Links
- 102000037865 fusion proteins Human genes 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000008672 reprogramming Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/804—Blood cells [leukemia, lymphoma]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862641159P | 2018-03-09 | 2018-03-09 | |
PCT/US2019/021315 WO2019173693A1 (en) | 2018-03-09 | 2019-03-08 | Compositions and methods for tcr reprogramming using fusion proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202008721SA true SG11202008721SA (en) | 2020-10-29 |
Family
ID=67846339
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202008721SA SG11202008721SA (en) | 2018-03-09 | 2019-03-08 | Compositions and methods for tcr reprogramming using fusion proteins |
Country Status (12)
Country | Link |
---|---|
US (1) | US20210361704A1 (en) |
EP (1) | EP3765039A4 (en) |
JP (1) | JP2021515598A (en) |
KR (1) | KR20200130383A (en) |
CN (1) | CN111954714A (en) |
AU (1) | AU2019231792A1 (en) |
BR (1) | BR112020018173A2 (en) |
CA (1) | CA3093449A1 (en) |
EA (1) | EA202092093A1 (en) |
MX (1) | MX2020009371A (en) |
SG (1) | SG11202008721SA (en) |
WO (1) | WO2019173693A1 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107995913B (en) | 2015-05-18 | 2022-02-11 | T细胞受体治疗公司 | Compositions and methods for reprogramming TCRs using fusion proteins |
WO2018026953A1 (en) | 2016-08-02 | 2018-02-08 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
CN109689686B (en) | 2016-10-07 | 2020-08-25 | T细胞受体治疗公司 | Compositions and methods for T cell receptor weight programming using fusion proteins |
CA3044593A1 (en) | 2016-11-22 | 2018-05-31 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
WO2021035170A1 (en) * | 2019-08-21 | 2021-02-25 | Precision Biosciences, Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
KR20220078607A (en) * | 2019-09-12 | 2022-06-10 | 티씨알2 테라퓨틱스 인크. | Compositions and methods for TCR reprogramming using fusion proteins |
WO2021133959A2 (en) * | 2019-12-24 | 2021-07-01 | TCR2 Therapeutics Inc. | Compositions and methods for gamma delta tcr reprogramming using fusion proteins |
CA3191448A1 (en) * | 2020-08-12 | 2022-02-17 | Migal Galilee Research Institute Ltd. | Alloreactive immune cell-distancing device and uses thereof for protecting donor-derived cells from allorejection |
CN117480247A (en) * | 2021-04-15 | 2024-01-30 | 恺兴生命科技(上海)有限公司 | Chimeric T cell receptor and uses thereof |
WO2023179795A1 (en) * | 2022-03-25 | 2023-09-28 | 立凌生物制药(苏州)有限公司 | Method for rapidly, simply and conveniently obtaining correctly paired tcrs, and obtained tcrs |
WO2023246911A1 (en) * | 2022-06-24 | 2023-12-28 | 北京可瑞生物科技有限公司 | T cell receptor-based bispecific polypeptide molecule and use thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003208839A1 (en) * | 2002-02-13 | 2003-09-04 | Micromet Ag | De-immunized (poly)peptide constructs |
US9181527B2 (en) * | 2009-10-29 | 2015-11-10 | The Trustees Of Dartmouth College | T cell receptor-deficient T cell compositions |
BR112014029417B1 (en) * | 2012-05-25 | 2023-03-07 | Cellectis | EX VIVO METHOD FOR THE PREPARATION OF T CELLS FOR IMMUNOTHERAPY |
CN107995913B (en) * | 2015-05-18 | 2022-02-11 | T细胞受体治疗公司 | Compositions and methods for reprogramming TCRs using fusion proteins |
FI3468997T3 (en) * | 2016-06-08 | 2023-10-31 | Xencor Inc | Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b |
CA3044593A1 (en) * | 2016-11-22 | 2018-05-31 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
JP2020513754A (en) * | 2016-12-21 | 2020-05-21 | ティーシーアール2 セラピューティクス インク. | T cells engineered for cancer treatment |
-
2019
- 2019-03-08 KR KR1020207028766A patent/KR20200130383A/en active Search and Examination
- 2019-03-08 CN CN201980023038.1A patent/CN111954714A/en active Pending
- 2019-03-08 BR BR112020018173-0A patent/BR112020018173A2/en not_active IP Right Cessation
- 2019-03-08 MX MX2020009371A patent/MX2020009371A/en unknown
- 2019-03-08 AU AU2019231792A patent/AU2019231792A1/en not_active Abandoned
- 2019-03-08 CA CA3093449A patent/CA3093449A1/en active Pending
- 2019-03-08 EP EP19763494.2A patent/EP3765039A4/en active Pending
- 2019-03-08 SG SG11202008721SA patent/SG11202008721SA/en unknown
- 2019-03-08 US US16/979,380 patent/US20210361704A1/en not_active Abandoned
- 2019-03-08 WO PCT/US2019/021315 patent/WO2019173693A1/en unknown
- 2019-03-08 JP JP2020571330A patent/JP2021515598A/en not_active Withdrawn
- 2019-03-08 EA EA202092093A patent/EA202092093A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
EA202092093A1 (en) | 2021-06-28 |
CN111954714A (en) | 2020-11-17 |
WO2019173693A1 (en) | 2019-09-12 |
EP3765039A1 (en) | 2021-01-20 |
MX2020009371A (en) | 2021-01-08 |
BR112020018173A2 (en) | 2021-04-27 |
US20210361704A1 (en) | 2021-11-25 |
EP3765039A4 (en) | 2021-12-08 |
AU2019231792A1 (en) | 2020-10-22 |
JP2021515598A (en) | 2021-06-24 |
KR20200130383A (en) | 2020-11-18 |
CA3093449A1 (en) | 2019-09-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB2564823B8 (en) | Compositions and methods for TCR reprogramming using fusion proteins | |
HK1252643A1 (en) | Compositions and methods for tcr reprogramming using fusion proteins | |
SG11202008721SA (en) | Compositions and methods for tcr reprogramming using fusion proteins | |
SG11202100838QA (en) | Compositions and methods for tcr reprogramming using target specific fusion proteins | |
EP3959322A4 (en) | Compositions and methods for tcr reprogramming using fusion proteins | |
SG11202012004SA (en) | Rna-targeting fusion protein compositions and methods for use | |
SG11202101811VA (en) | Compositions and methods for tcr reprogramming using fusion proteins | |
IL279510A (en) | Progranulin-fc polypeptide fusion proteins and uses thereof | |
IL291236A (en) | Compositions and methods for tcr reprogramming using fusion proteins | |
ZA202100125B (en) | Novel fusion protein specific for cd137 and pd-l1 | |
IL275691A (en) | Single-domain antibody-cytosine deaminase fusion proteins | |
EP3941494A4 (en) | Compositions and methods for tcr reprogramming using fusion proteins | |
SG11202101904UA (en) | Spd-1 variant - fc fusion proteins | |
SG11202104912SA (en) | Fusion protein and use thereof | |
EP3703676A4 (en) | Composition and method for modifying polypeptides | |
ZA202102533B (en) | Fusion protein | |
ZA202007491B (en) | Stable fusion protein formulation | |
PT3830120T (en) | Novel fusion protein specific for cd137 and pd-l1 |